Navigation Links
Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
Date:7/28/2011

herited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A is the most common type of hemophilia and is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. Approximately 400,000 people around the world have hemophilia.

About Bayer HealthCare

Bayer HealthCare is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-looking statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER and the Bayer Cross are registered trademarks of Bayer.  

KN28000511


'/>"/>
SOURCE Bayer HealthCare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
(Date:9/18/2014)... 18, 2014 After 6 months of ... finally here - the new programme for the next Cool ... of our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA ... programme that is broad and yet specific, focused and yet ...
(Date:9/18/2014)... 18, 2014   Regulus Therapeutics Inc . ... leading the discovery and development of innovative medicines ... ATHENA natural history of disease study in patients ... with no approved therapy. The ATHENA study is ... function markers such as Glomerular Filtration Rate ("GFR"), ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... March 31, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... is initiating launch activities of Nulecit™ (sodium ferric ... of GeneraMedix Inc.,s, Abbreviated New Drug Application (ANDA). ... alternative to Sanofi-Aventis, Ferrlecit ® .  In July ...
... DIEGO, March 31, 2011 OncoSec Medical Inc. (OTC BB: ... tumor cancers, announced today that it has raised more than ... to three institutional investors. OncoSec issued 1,456,000 units at a ... Each unit consisted of one share of common stock and ...
Cached Medicine Technology:Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 3Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 4OncoSec Medical Closes $1.1M Financing 2
(Date:9/18/2014)... Springs, FL (PRWEB) September 18, 2014 It ... and run, sprint or walk for healthier and happier kids. ... support and participate in the 4th Annual Miami Children’s Hospital ... Wheels. http://www.hyundaihopeonwheels.org , The 5K will ... finishing location will be outside of Coral Gables City Hall ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... . Two ... ,International Space Station Research Competition, with their project ,Egypt ... will see the International Space Station crew perform experiments ... proteins of the hepatitis C virus under microgravity conditions. ... Station is scheduled to lift off from Cape Canaveral ...
(Date:9/18/2014)... 18, 2014 PlatinumCode, a leading ... collection products for the healthcare industry, announced earlier ... five percent of their profits of the sale ... In making the announcement, PlatinumCode has launched various ... providing clinical and hospital labs with their popular ...
(Date:9/18/2014)... 2014 T-System Inc. today announced ... documentation system — EV™ for physicians ... assessing several best-of-breed solutions, Holyoke chose T-System’s solution ... physician productivity and reimbursement, but also its ability ... still be used to capture emergency department, (ED) ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Hepatitis C virus proteins in space 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2
... active participation in their communities has led researchers to define this ... now be considered a distinct retirement role, according to an article ... (Volume 48, Number 3). , The authors identify civic ... one day per week that directly impact the local community. ...
... 6 hours for participants in phase II trial ... gout drug called pegloticase lowered levels of uric acid ... hours in most patients. , That,s the conclusion of ... and Savient Pharmaceuticals, the company that,s developing the drug. ...
... Ill., Sept. 3 Z Trim Holdings,Inc. (Amex: ... 2, 2008, the Company,entered into private placement subscription ... of convertible notes and warrants, for an,aggregate offering ... a,"Unit" and collectively, the "Units") consists of a ...
... 28,000 ratings and comments are overwhelmingly positive, ... of,Regence members would recommend their doctor to others, ... member Web site -- myRegence.com. A,"Member Feedback" feature ... on their experiences with individual providers, including,physicians, dentists, ...
... (doi:10.1016/j.clim.2008.06.009) published in Clinical Immunology, the official ... new method enabling the detection of multiple parameters of ... specific blood cells from an individual with type 1 ... play in the development of the disease and during ...
... on earnings and productivity for healthcare professionals in the United States, ... decrease in patient loads. , ... New York, NY ... focusing on earnings and productivity for physicians in America features some ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: